As of Jun 12, 2026, the Smith & Nephew stock's PE ratio is 21.23. This results from the current EPS of $1.44 and stock price of $30.57.
The PE ratio of Smith & Nephew has averaged 32.66 over the last ten years. The current price-to-earnings ratio of 21.23 is 35% less than the historical average.
Maximum annual increase: 82.77% in 2022
Maximum annual decrease: -55.84% in 2016
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2025 | 22.78 | -12.89% | $32.81 | $1.44 |
| 2024 | 26.15 | -42.49% | $24.58 | $0.94 |
| 2023 | 45.47 | -13.77% | $27.28 | $0.6 |
| 2022 | 52.73 | 82.77% | $26.89 | $0.51 |
| 2021 | 28.85 | -29.53% | $34.62 | $1.2 |
| 2020 | 40.94 | 16.67% | $42.17 | $1.03 |
| 2019 | 35.09 | 42.7% | $48.07 | $1.37 |
| 2018 | 24.59 | 23.63% | $37.38 | $1.52 |
| 2017 | 19.89 | 16.38% | $35.01 | $1.76 |
| 2016 | 17.09 | -55.84% | $30.08 | $1.76 |
| 2015 | 38.7 | 17.99% | $35.6 | $0.92 |
| 2014 | 32.8 | 40.59% | $36.74 | $1.12 |
| 2013 | 23.33 | 69.55% | $28.7 | $1.23 |
| 2012 | 13.76 | -7.84% | $22.16 | $1.61 |
| 2011 | 14.93 | -1.26% | $19.26 | $1.29 |
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Dec 2025 | 22.78 | -15.57% | $32.81 | $1.44 |
| Jun 2025 | 26.98 | 3.17% | $30.22 | $1.12 |
| Dec 2024 | 26.15 | -26.13% | $24.58 | $0.94 |
| Jun 2024 | 35.4 | -22.15% | $24.78 | $0.7 |
| Dec 2023 | 45.47 | -29.5% | $27.28 | $0.6 |
| Jul 2023 | 64.5 | 22.32% | $32.25 | $0.5 |
| Dec 2022 | 52.73 | 113.05% | $26.89 | $0.51 |
| Jul 2022 | 24.75 | -14.21% | $27.97 | $1.13 |
| Dec 2021 | 28.85 | -17.71% | $34.62 | $1.2 |
| Jul 2021 | 35.06 | -14.36% | $44.17 | $1.26 |
| Dec 2020 | 40.94 | -2.06% | $42.17 | $1.03 |
| Jun 2020 | 41.8 | 19.12% | $37.62 | $0.9 |
| Dec 2019 | 35.09 | 28.96% | $48.07 | $1.37 |
| Jun 2019 | 27.21 | 10.65% | $43.54 | $1.6 |
| Dec 2018 | 24.59 | 7.47% | $37.38 | $1.52 |
The Historical Valuation Regime chart shows where the stock's current valuation sits relative to its own historical valuation range over the selected lookback period.
This is a history-relative tool, not a market-relative percentile. It does not compare the stock to other companies. Instead, it compares each historical valuation reading to the stock's own past readings.
The threshold lines are calculated them from the stock's real historical values using percentile interpolation. That is why some colored bands are narrow while others are wide: the band widths reflect how the stock actually traded through time.
| Historical percentile | Regime | Chart meaning |
|---|---|---|
| 0-10 | Historically Low | Deep cheap zone |
| >10-25 | Below Average | Cheap relative to history |
| >25-75 | Average | Within the normal historical range |
| >75-90 | Above Average | Expensive relative to history |
| >90-100 | Historically High | Extreme or stretched valuation |
| Chart element | What it tells you |
|---|---|
| Main line | The actual historical valuation values over time for the selected metric. |
| Dashed horizontal lines | The stock's computed P10, P25, Median, P75, and P90 thresholds for the selected period. |
| Colored bands | The historical valuation zones between those thresholds. |
| Metric boxes | Current ratio, historical median, current percentile, and current regime. |
| Timeline strip | A condensed regime history showing how the stock moved between cheap, fair, and expensive states across each observation. |
Current Percentile is the percentile rank of the latest valid historical observation within the selected lookback range.
Current Regime is assigned directly from the latest observation's percentile bucket using the fixed 10 / 25 / 75 / 90 cutoffs shown above.
This chart is most useful for answering a narrow question: Is this stock trading high, low, or normal relative to its own history? It works best alongside growth, profitability, and forward-looking business analysis, because a stock can deserve a higher or lower regime if its business quality has changed.
Currently, SNN's PE ratio is lower than the 3, 5 and 10-year averages.
Smith & Nephew's P/E of 21.23 is below the Healthcare sector, the industry and its peers average. Looking at its Healthcare sector average of 24.29, Smith & Nephew's P/E is 13% lower.
When compared to its peers JNJ and ABT, SNN's PE ratio is lower, but it is higher than BSX's. Smith & Nephew's PE ratio is trading below the peer group average of 31.52.
| Stock name | PE ratio | Market cap |
|---|---|---|
| BSX Boston Scientific Corp | 19.37 | $69.37B |
| SNN Smith & Nephew plc | 21.16 | $13.37B |
| MDT Medtronic plc | 22.34 | $103.24B |
| ZBH Zimmer Biomet Holdings Inc | 22.81 | $17.08B |
| ABT Abbott Laboratories | 24.69 | $154.41B |
| JNJ Johnson & Johnson | 27.01 | $567.65B |
| SYK Stryker Corp | 35.19 | $117.91B |
| BDX Becton Dickinson & Co | 36.83 | $40.08B |
| EW Edwards Lifesciences Corp | 46.3 | $50.38B |
| ISRG Intuitive Surgical Inc | 49.76 | $147.33B |
| BAX Baxter International Inc | N/A | $10.75B |
SNN stock has a price to earnings ratio of 21.23 as of Jun 12, 2026.
As an average over the last 3 years, SNN stock has a PE ratio of 36.88.
As an average over the last 5 years, SNN stock has a PE ratio of 36.27.
SNN's price to earnings ratio is currently 35% below its 10-year historical average.
You can calculate the P/E ratio by dividing the most recent stock price by the trailing twelve months earnings per share(EPS). As of today (Jun 12, 2026), Smith & Nephew's stock price is $30.57. The earnings per share for the trailing twelve months (TTM) ending Dec 2025 is $1.44. Therefore, Smith & Nephew's price to earnings ratio for today is 21.23. PE RATIO(21.23) = STOCK PRICE($30.57) / TTM EPS($1.44)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.